| __timestamp | Rhythm Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5280000 | 47795223 |
| Thursday, January 1, 2015 | 7148000 | 50426000 |
| Friday, January 1, 2016 | 19594000 | 70853000 |
| Sunday, January 1, 2017 | 22894000 | 78168000 |
| Monday, January 1, 2018 | 50337000 | 123757000 |
| Tuesday, January 1, 2019 | 109450000 | 140963000 |
| Wednesday, January 1, 2020 | 90450000 | 131773000 |
| Friday, January 1, 2021 | 104128000 | 210328000 |
| Saturday, January 1, 2022 | 108630000 | 235780000 |
| Sunday, January 1, 2023 | 134951000 | 244990000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Rhythm Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Travere Therapeutics consistently outpaced Rhythm Pharmaceuticals in R&D expenditure, with a notable 413% increase from 2014 to 2023. In 2023, Travere's R&D expenses reached approximately $245 million, nearly doubling Rhythm's $135 million. This trend underscores Travere's aggressive pursuit of new therapies.
Rhythm Pharmaceuticals, while trailing in absolute spending, showed a remarkable growth of over 2,400% in R&D expenses from 2014 to 2023, highlighting its strategic focus on developing innovative treatments. This data not only reflects the companies' financial priorities but also their potential impact on future healthcare advancements.
Comparing Innovation Spending: Amgen Inc. and Rhythm Pharmaceuticals, Inc.
Analyzing R&D Budgets: Vertex Pharmaceuticals Incorporated vs Rhythm Pharmaceuticals, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Research and Development Investment: Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Research and Development Investment: Madrigal Pharmaceuticals, Inc. vs Rhythm Pharmaceuticals, Inc.
Analyzing R&D Budgets: Opthea Limited vs Rhythm Pharmaceuticals, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs Travere Therapeutics, Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Travere Therapeutics, Inc. vs Xencor, Inc.